Pharma BD Deal Intelligence
A desperation sale dressed as a gene-therapy bet: Lilly paid just $3.56/share cash upfront for cash-strapped Adverum, with the bulk of the up-to-$261M value locked in a non-tradable CVR tied to Ixo-vec regulatory approval and $1B annual-sales milestones that may never pay out.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie and REGENXBIO today announced updates on the ABBV-RGX-314 clinical program for wet age-related macular degeneration and diabetic retinopathy. Data from…
Eli Lilly announced plans to acquire Adverum Biotechnologies in a transaction valued at up to approximately $261 million, gaining access to Ixo-vec, a Phase…
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition. The tender offer by Flying Tigers Acquisition Corporation expired…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Lilly agreed to acquire Adverum on October 24, 2025 for $3.56/share cash at closing plus a non-tradable CVR worth up to $8.91/share tied to Ixo-vec regulatory approval and $1B annual-sales milestones, for total deal value up to ~$261M. The all-cash tender offer (via subsidiary Flying Tigers Acquisition Corporation) expired at 11:59 p.m. ET on December 8, 2025 with ~64% of shares tendered, and Lilly completed the acquisition on December 9, 2025 through a Section 251(h) second-step merger; Adverum became a wholly owned Lilly subsidiary and was delisted. The deal gives Lilly Ixo-vec (ixoberogene soroparvovec), a one-time intravitreal AAV gene therapy in Phase 3 for wet AMD, extending Lilly's gene therapy push following its Verve acquisition earlier in 2025.
1 US cases/yr · $15.4B Global AMD market 2024 ($15.43B, wet AMD dominant segment, projected $25.8B by 2034) · $9.5B Eylea (aflibercept) 2024 global revenue; Regeneron ~62.5% US-derived
Wet age-related macular degeneration (wet AMD, neovascular AMD) is a leading cause of irreversible vision loss in adults over 65, driven by VEGF-mediated choroidal neovascularization that causes macular hemorrhage, fluid accumulation, and photoreceptor loss. The American Academy of Ophthalmology estimates approximately 1.5 million Americans have late-stage AMD and 18.3 million have early AMD, with the wet subtype representing roughly 10-15% of all AMD cases (approximately 1-1.5 million US wet AMD patients). Standard-of-care is intravitreal anti-VEGF injection therapy: Regeneron/Bayer's Eylea (aflibercept) and Eylea HD, Roche/Genentech's Vabysmo (faricimab, dual VEGF-A/Ang-2), and Roche's Lucentis (ranibizumab) plus biosimilars. The therapeutic burden is substantial: patients typically require injections every 4-16 weeks indefinitely, and real-world data show 30-40% of patients discontinue within two years due to injection fatigue, access barriers, or caregiver burden. The 2024 global AMD market was $15.4B with wet AMD as the dominant revenue segment, projected to reach $25.8B by 2034. A one-time gene therapy delivering sustained intraocular VEGF suppression addresses the single largest unmet need in the category: treatment burden reduction.
The wet AMD anti-VEGF market is dominated by Regeneron/Bayer's Eylea and Eylea HD (aflibercept, ~$9.5B 2024 global revenue, ~43.7% AMD market share), Roche's Vabysmo (faricimab, dual VEGF-A/Ang-2 bispecific, q16w dosing), Roche's Lucentis (ranibizumab) plus biosimilars Byooviz (Samsung Bioepis/Biogen) and Cimerli (Coherus), Apellis's Syfovre (pegcetacoplan) for geographic atrophy/dry AMD, and Astellas's Izervay (avacincaptad pegol) for GA. The disruptive one-time gene therapy class is now led by Adverum's Ixo-vec (ixoberogene soroparvovec, AAV.7m8 aflibercept, Phase 3 ARTEMIS enrolling 284 patients, data 1Q 2027), AbbVie/Regenxbio's ABBV-RGX-314 (AAV8 anti-VEGF Fab, Phase 3 ATMOSPHERE and ASCENT subretinal plus AAVIATE suprachoroidal delivery, pivotal data 2026, 85% injection reduction in high-dose suprachoroidal cohort), and 4D Molecular Therapeutics' 4D-150 (AAV R100 aflibercept/anti-VEGF-C miRNA, Phase 3 4FRONT-1/2, 83% injection-burden reduction in PRISM). Lilly's acquisition is its second gene-therapy move of 2025 (following the Verve cardiovascular acquisition) and positions Ixo-vec as a challenger asset behind ABBV-RGX-314's earlier Phase 3 readout timeline.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Adverum Biotechnologies, Inc. (this deal) | 2025 | $261M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2025 deals · Eli Lilly and Company deals · Ophthalmology deals